CORTESI, LISA

CORTESI, LISA  

Mostra records
Risultati 1 - 12 di 12 (tempo di esecuzione: 0.016 secondi).
Titolo Data di pubblicazione Autore(i) File
Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework 1-gen-2021 Tenedini, E; Celestini, F; Iapicca, P; Marino, M; Castellano, S; Artuso, L; Biagiarelli, F; Cortesi, L; Toss, A; Barbieri, E; Roncucci, L; Pedroni, M; Manfredini, R; Luppi, M; Trenti, T; Tagliafico, E
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 1-gen-2020 Toss, A.; Molinaro, E.; Venturelli, M.; Domati, F.; Marcheselli, L.; Piana, S.; Barbieri, E.; Grandi, G.; Piombino, C.; Marchi, I.; Tenedini, E.; Tagliafico, E.; Tazzioli, G.; Cortesi, L.
The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance 1-gen-2021 Grandi, G.; Fiocchi, F.; Cortesi, L.; Toss, A.; Boselli, F.; Sammarini, M.; Sighinolfi, G.; Facchinetti, F.
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 1-gen-2020 Omarini, C.; Piacentini, F.; Sperduti, I.; Barbolini, M.; Isca, C.; Toss, A.; Cortesi, L.; Barbieri, E.; Dominici, M.; Moscetti, L.
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 1-gen-2019 Toss, A.; Venturelli, M.; Sperduti, I.; Molinaro, E.; Isca, C.; Barbieri, E.; Piacentini, F.; Omarini, C.; Cortesi, L.; Cascinu, S.; Moscetti, L.
Hereditary ovarian cancers: State of the art 1-gen-2019 Toss, A.; Molinaro, E.; Sammarini, M.; Del Savio, M. C.; Cortesi, L.; Facchinetti, F.; Grandi, G.
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 1-gen-2020 Cortesi, L.; Sebastiani, F.; Iannone, A.; Marcheselli, L.; Venturelli, M.; Piombino, C.; Toss, A.; Federico, M.
Male mammary myofibroblastoma: Two case reports and brief review of literature 1-gen-2020 Venturelli, M.; Toss, A.; Cortesi, L.; Gambini, A.; Andreotti, A.; Cascinu, S.; Tazzioli, G.; Moscetti, L.
PARP inhibitors for the treatment of ovarian cancer 1-gen-2018 Cortesi, Lisa; Toss, A.; Cucinotto, I.
Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which? 1-gen-2020 Grandi, G.; Caroli, M.; Cortesi, L.; Toss, A.; Tazzioli, G.; Facchinetti, F.
The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: A prospective cohort, other biomarker controlled, study 1-gen-2020 Grandi, G.; Del Savio, M. C.; Sammarini, M.; Cortesi, L.; Toss, A.; Piombino, C.; Facchinetti, F.
The generally low sensitivity of CA125 for FIGO stage I ovarian cancer diagnosis increases for endometrioid histotype 1-gen-2020 Grandi, G.; Perrone, A. M.; Toss, A.; Vitagliano, A.; Friso, S.; Facchinetti, F.; Cortesi, L.; Cascinu, S.; Deiaco, P.